Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) Urological Tumour Registry-Reference-Cited by-同舟云学术

Stage, grade and pathological characteristics of bladder cancer in the UK: British Association of Urological Surgeons (BAUS) Urological Tumour Registry

Published:2014-01-22 Issue:6 Volume:113 Page:924-930
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Boustead Gregory B.¹,Fowler Sarah²,Swamy Rajiv¹,Kocklebergh Roger³,Hounsome Luke⁴,

Affiliation:

1. Lister Hospital; Stevenage Hertfordshire UK

2. BAUS Section of Oncology; Bristol UK

3. Leicester General Hospital; Leicester UK

4. South West Public Health Observatory; Bristol UK

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12468/fullpdf

Reference21 articles.

1. Bladder cancer: a major public health issue;Grasso;Eur Urol Suppl,2008

2. The health economics of bladder cancer: a comprehensive review of the published literature;Botteman;Pharmacoeconomics.,2003

3. Quality of life aspects of bladder cancer: a review of the literature;Botteman;Qual Life Res,2003

4. Can we still afford bladder cancer?;Stenzl;Curr Opin Urol,2008

5. Occupational cancer in Britain. Urinary tract cancers: bladder and kidney;Brown;Br J Cancer,2012

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma;Journal of Health Economics and Outcomes Research;2024-08-20

2. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma;Journal of Health Economics and Outcomes Research;2024-08-20

3. Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT;Health Technology Assessment;2024-08

4. Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions;Cancers;2024-06-29

5. Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion;Clinical Genitourinary Cancer;2024-04